I’m a Research Associate at the Centre for Health Economics & Policy Innovation working on a project funded by the Gatsby Foundation on the impact of innovations on R&D models in the biopharma sector.
Before joining Imperial College, I worked for the European Medicines Agency and UK Research and Innovation, where I was involved in the incentivisation and appraisal of biopharmaceutical innovation for children, rare diseases and COVID-19.
My academic background is in biomedicine, clinical neurosciences, and health policy. I hold a PhD in Clinical Neurosciences from the University of Cambridge and an MSc in Health Policy from Imperial College London for which I conducted research on pharmaceutical innovation in the EU.
et al., 2022, Choosing drugs for UK COVID-19 treatment trials COMMENT, Nature Reviews Drug Discovery, Vol:21, ISSN:1474-1776, Pages:81-82
et al., 2019, Defining orphan conditions in the context of the European orphan regulation: challenges and evolution., Nature Reviews. Drug Discovery
et al., 2018, Marketing authorisation of orphan medicines in Europe from 2000 to 2013., Drug Discovery Today
et al., 2018, Demonstrating significant benefit of orphan medicines: analysis of 15 years of experience in Europe., Drug Discovery Today
et al., 2018, Establishing rarity in the context of orphan medicinal product designation in the European Union., Drug Discovery Today
et al., 2015, Regulatory watch: Impact of scientific advice from the European Medicines Agency., Nature Reviews. Drug Discovery